166th ENMC International Workshop on Collagen type VI-related Myopathies, 22-24 May 2009, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 20, Issue 5, 2010, Pages 346-354

  Allamand, Valérie ^a   Merlini, Luciano ^b   Bushby, Kate ^c  

^a INSERM   (France)

^b UNIVERSITY OF FERRARA   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 6; COLLAGEN TYPE 6 A1; COLLAGEN TYPE 6 A2; COLLAGEN TYPE 6 A3; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; OMIGAPIL; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CARTILAGE CELL; CLINICAL TRIAL; COLLAGEN TYPE 6 RELATED MYOPATHY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ENDOPLASMIC RETICULUM; EXTERNAL BEAM RADIOTHERAPY; FIBROBLAST; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LIMB GIRDLE MUSCULAR DYSTROPHY; MEDICAL EDUCATION; MISSENSE MUTATION; MUSCULAR DYSTROPHY; MYOPATHY; NEUROMUSCULAR DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT RESPONSE; WORKSHOP;

COLLAGEN TYPE VI; DATABASES, FACTUAL; HUMANS; MUSCLE, SKELETAL; MUSCULAR DISEASES; NETHERLANDS; SEQUENCE ANALYSIS, DNA;

EID: 77952012386     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.02.012     Document Type: Article

References (54)

1. Gualandi F., Urciuolo A., Martoni E., et al. Autosomal recessive Bethlem myopathy. Neurology 2009, 73:1883-1891.
2. Foley A.R., Hu Y., Zou Y., et al. Autosomal recessive inheritance of classic Bethlem myopathy. Neuromusc Disord 2009, 19:813-817.
3. Pepe G., Giusti B., Bertini E., et al. A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the [alpha]1(VI) collagen chain in an Italian family affected by Bethlem myopathy. Biochem Biophys Res Com 1999, 258:802-807.
4. Merlini L., Bernardi P. Therapy of collagen VI-related myopathies (Bethlem and Ullrich). Neurotherapeutics 2008, 5:613-618.
5. Pepe G., de Visser M., Bertini E., et al. Bethlem myopathy (Bethlem) 86th ENMC international workshop, 10-11 November 2000, Naarden, The Netherlands. Neuromusc Disord 2002, 12:296-305.
6. Ishikawa H., Sugie K., Murayama K., et al. Ullrich disease due to deficiency of collagen VI in the sarcolemma. Neurology 2004, 62:620-623.
7. Arts W., Bethlem J., Volkers W. Further investigations on benign myopathy with autosomal dominant inheritance. J Neurol 1978, 217:201-206.
8. Bethlem J., Van Wijngaarden G.K. Benign myopathy with autosomal dominant inheritance: a report of three pedigrees. Brain 1976, 99:91-100.
9. Jobsis G.J., Boers J.M., Barth P.G., de Visser M. Bethlem myopathy: a slowly progressive congenital muscular dystrophy with contractures. Brain 1999, 122:649-655.
10. Mohire M.D., Tandan R., Fries T.J., et al. Early-onset benign autosomal dominant limb-girdle myopathy with contractures (Bethlem myopathy). Neurology 1988, 38:573-580.
11. Haq R., Speer M., Chu M., Tandan R. Respiratory muscle involvement in Bethlem myopathy. Neurology 1999, 52:174-176.
12. van der Kooi A.J., de Voogt W.G., Bertini E., et al. Cardiac and Pulmonary Investigations in Bethlem Myopathy. Arch Neurol 2006, 63:1617-1621.
13. Bradley W., Hudgson P., Gardner-Medwin D., Walton J.N. The syndrome of myosclerosis. J Neurol Neurosurg Psychiatry 1973, 36:651-660.
14. Quijano Roy S., Allamand V., Riahi N., et al. Predictive factors of severity and management of respiratory and orthopaedic complications in 16 Ullrich CMD patients. Neuromusc. Disord. 2007, 17:844.
15. Nadeau A., Kinali M., Main M., et al. Natural history of Ullrich congenital muscular dystrophy. Neurology 2009, 73:25-31.
16. Hicks D., Lampe A.K., Barresi R., et al. A refined diagnostic algorithm for Bethlem myopathy. Neurology 2008, 70:1192-1199.
17. Jimenez-Mallebrera C., Maioli M.A., Kim J., et al. A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Neuromusc Disord 2006, 16:571-582.
18. Mercuri E., Lampe A., Allsop J., et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromusc Disord 2005, 15:303-310.
19. Lampe A.K., Dunn D.M., Von Niederhausern A.C., et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. J Med Genet 2005, 42(2):108-120.
20. Minamitani T., Ikuta T., Saito Y., et al. Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Exp Cell Res 2004, 298:305-315.
21. Kirschner J., Hausser I., Zou Y., et al. Ullrich congenital muscular dystrophy: connective tissue abnormalities in the skin support overlap with Ehlers-Danlos syndromes. Am J Med Genet A 2005, 132A:296-301.
22. Sabatelli P., Bonaldo P., Lattanzi G., et al. Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol 2001, 20:475-486.
23. Harumiya S., Gibson M., Koshihara Y. Antisense suppression of collagen VI synthesis results in reduced expression of collagen I in normal human osteoblast-like cells. Biosci Biotechnol Biochem 2002, 66:2743-2747.
24. Alexopoulos L., Youn I., Bonaldo P., Guilak F. Developmental and osteoarthritic changes in Col6a1-knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix. Arthritis Rheum. 2009, 60:771-779.
25. Cheng J.S., Dubal D.B., Kim D.H., et al. Collagen VI protects neurons against A[beta] toxicity. Nat Neurosci 2009, 12:119-121.
26. Leitinger B., Hohenester E. Mammalian collagen receptors. Matrix Biol 2007, 26:146-155.
27. Stallcup W. The NG2 proteoglycan: past insights and future prospects. J Neurocytol 2002, 31:423-435.
28. Somasundaram R., Ruehl M., Tiling N., et al. Collagens serve as an extracellular store of bioactive interleukin 2. J Biol Chem 2000, 275:38170-38175.
29. Somasundaram R., Ruehl M., Schaefer B., et al. Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J Biol Chem 2002, 277:3242-3246.
30. Ruehl M., Somasundaram R., Schoenfelder I., et al. The epithelial mitogen keratinocyte growth factor binds to collagens via the consensus sequence glycine-proline-hydroxyproline. J Biol Chem 2002, 277:26872-26878.
31. Somasundaram R., Schuppan D. Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB). J Biol Chem 1996, 271:26884-26891.
32. Zou Y.M.D., Zhang R.-Z.M.D., Sabatelli P.B., Chu M.-L.P., Bönnemann C.G.M.D. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol 2008, 67:144-154.
33. Braghetta P., Ferrari A., Fabbro C., et al. An enhancer required for transcription of the Col6a1 gene in muscle connective tissue is induced by signals released from muscle cells. Exp Cell Res 2008, 314:3508-3518.
34. Fitzgerald J., Rich C., Zhou F.H., Hansen U. Three novel collagen VI chains, {alpha}4(VI), {alpha}5(VI), and {alpha}6(VI). J Biol Chem 2008, 283:20170-20180.
35. Gara S.K., Grumati P., Urciuolo A., et al. Three novel collagen VI chains with high homology to the {alpha}3 chain. J Biol Chem 2008, 283:10658-10670.
36. Wagener R., Gara S.K., Kobbe B., Paulsson M., Zaucke F. The knee osteoarthritis susceptibility locus DVWA on chromosome 3p24.3 is the 5′ part of the split COL6A4 gene. Matrix Biol 2009, 28:307-310.
37. Miyamoto Y., Shi D., Nakajima M., et al. Common variants in DVWA on chromosome 3p24.3 are associated with susceptibility to knee osteoarthritis. Nat Genet 2008, 40:994-998.
38. Söderhäll C., Marenholz I., Kerscher T., et al. Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. PLoS Biol 2007, 5:e242.
39. Allamand V., Gartioux C., Lacène E., et al. Endoplasmic reticulum retention of COL6 chains in Ullrich congenital muscular dystrophy. Neuromusc Disord 2007, 17:833.
40. Bonaldo P., Braghetta P., Zanetti M., et al. Collagen VI deficiency induces early onset myopathy in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet 1998, 7:2135-2140.
41. Irwin W., Bergamin N., Sabatelli P., et al. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 2003, 35:367-371.
42. Palma E., Tiepolo T., Angelin A., et al. Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Hum Mol Genet 2009, 18:2024-2031.
43. Hicks D., Lampe A.K., Laval S.H., et al. Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain 2009, 132:147-155.
44. Al-Rubeai M., Singh R.P. Apoptosis in cell culture. Curr Opin Biotechnol 1998, 9:152-156.
45. Merlini L., Angelin A., Tiepolo T., et al. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Nat Acad Sci 2008, 105:5225-5229.
46. Angelin A., Tiepolo T., Sabatelli P., et al. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Nat Acad Sci 2007, 104:991-996.
47. Kragten E., Lalande I., Zimmermann K., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 1998, 273:5821-5828.
48. Erb M., Meinen S., Barzaghi P., et al. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-{alpha}2 deficiency. J Pharmacol Exp Ther 2009, 331(3):787-795.
49. Borel J., Baumann G., Chapman I., et al. In vivo pharmacological effects of cyclosporin and some analogues. Adv Pharmacol 1996, 35:115-246.
50. Tiepolo T., Angelin A., Palma E., et al. The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1 myopathic mice. Br J Pharmacol 2009, 157:1045-1052.
51. Millay D.P., Sargent M.A., Osinska H., et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008, 14:442-447.
52. Reutenauer J., Dorchies O., Patthey-Vuadens O., Vuagniaux G., Ruegg U. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol 2008, 155:574-584.
53. Hansson M.J., Mattiasson G., Månsson R., et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J Bioenerg Biomembr 2004, 36:407-413.
54. Sárközy A., Bushby K., Béroud C., Lochmüller H. 157th ENMC international workshop: patient registries for rare, inherited muscular disorders 25-27 January 2008 Naarden, The Netherlands. Neuromusc Disord 2008, 18:997-1001.